The latest on artificial intelligence transforming medicine

FDA Opens the Door to De-Identified Real-World Evidence in Regulatory Filings

The FDA has issued guidance that makes de-identified real-world evidence more usable in regulatory submissions, potentially broadening the data sources companies can bring to market. For drug and device developers, this could reduce reliance on traditional trials in some contexts while increasing pressure to prove data quality and provenance.